3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Neuroblastoma
13
Prostatic Neoplasms
11
Leukemia
11
Breast Neoplasms
11
Melanoma
8
Lymphoma
8
Lymphoma, Non-Hodgkin
7
Leukemia, Lymphocytic, Chronic, B-Cell
7
Neoplasm Metastasis
6
Myelodysplastic Syndromes
6
Multiple Myeloma
6
Leukemia, Myeloid, Acute
6
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
6
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Glioblastoma
5
Carcinoma, Non-Small-Cell Lung
5
Ovarian Neoplasms
4
Lymphoma, Large B-Cell, Diffuse
4
Fallopian Tube Neoplasms
4
Breast Neoplasms, Male
4
Lymphoma, Follicular
3
Kidney Neoplasms
3
Hodgkin Disease
3
Glioma
3
Carcinoma, Renal Cell
3
Osteosarcoma
2
Neoplasms, Plasma Cell
2
Neoplasms
2
Myeloproliferative Disorders
2
Lymphoma, Mantle-Cell
2
Interventions
sargramostim
1
Temozolomide
1
Granulocyte-Macrophage Colony-Stimulating Factor
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Tetanus
×
Granulocyte-Macrophage Colony-Stimulating Factor
×
Clear all
NCT03927222
2024-04-08
I-ATTAC
Duke University
Phase 2
Terminated
6 enrolled
7 charts